• The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
• If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe

Menarini chooses Italy for its new €150 million manufacturing site.

Menarini Group announced its 2019 results en